Point-of-care virologic testing to improve outcomes of HIV-infected children

护理点病毒学检测可改善艾滋病毒感染儿童的预后

基本信息

项目摘要

DESCRIPTION (provided by applicant): Despite our best efforts to roll out mother-to-child HIV prevention services, many children in developing nations such as Zambia do not escape infection. Fortunately, life-saving antiretroviral therapy is now available in many settings, but i order for it to work, infected newborns must be identified and treatment started immediately. Diagnosis of infant HIV infection represents a major hurdle to this process. Unlike HIV testing in adults, infant diagnosis requires special laboratory equipment and personnel available only in sophisticated laboratories. As a result, most children either have no access to HIV diagnosis at all or must wait for weeks to receive their test result. In Zambia - as in many countries in the region - more than half of newborns who are tested and found to be infected never actually start treatment. The University of Cambridge has developed a new point-of-care (POC) test called "SAMBA" that can diagnose infant HIV infection by detecting HIV genetic material in the blood. Designed specifically for developing world settings, SAMBA results are ready in two hours. Two versions of the test are available, a qualitative test (for infant diagnosis) and a semi-quantitatie test (for treatment monitoring). This proposal describes a cluster-randomized trial of the SAMBA POC virologic test to improve outcomes of HIV-infected children in Zambia. The POC technology will be placed in primary care sites and serve two functions: (1) provision of same-day, early infant HIV diagnosis at 6 weeks of life for infants born to HIV-infected mothers, and (2) treatment monitoring of children on antiretroviral therapy. Twelve facilities will participate n the trial. Half of the sites will be randomly assigned to implement the POC technology and the other half will employ the current standard of care - where infant diagnosis is performed off site and treatment monitoring is based primarily upon clinical assessment. The trial's primary outcome will be the proportion of HIV-infected children in each study arm who remain alive, in care, and with no HIV circulating in their bloodstream (an indicator of treatment success) 18 months after their initial diagnosis. The study will be conducted by the Centre for Infectious Disease Research in Zambia (CIDRZ). Established in 2001, and led by the team proposing this study, CIDRZ has substantial experience with both NIH-sponsored research and PEPFAR-sponsored service implementation. PUBLIC HEALTH RELEVANCE: Although interventions to prevent mother-to-child HIV transmission are becoming increasingly available, many children in developing nations such as Zambia do not escape infection. Identifying infected newborns and starting immediate antiretroviral therapy has a profound survival effect. This proposal outlines a clinical trial to tst the field effectiveness of a new point- of-care diagnostic technology to identify infected children and start them immediately on life- saving antiretroviral therapy.
描述(申请人提供):尽管我们尽最大努力推出母婴艾滋病毒预防服务,但赞比亚等发展中国家的许多儿童无法逃脱感染。幸运的是,现在许多地方都有救命的抗逆转录病毒疗法,但我要求它发挥作用,必须识别受感染的新生儿,并立即开始治疗。婴儿艾滋病毒感染的诊断是这一进程的主要障碍。与成人艾滋病毒检测不同,婴儿诊断需要特殊的实验室设备和人员,只有在先进的实验室才能使用。因此,大多数儿童要么根本无法获得艾滋病毒诊断,要么必须等待数周才能收到检测结果。在赞比亚--就像该地区的许多国家一样--一半以上的新生儿在接受检测并被发现感染后,从未真正开始治疗。剑桥大学开发了一种名为“Samba”的新的护理点(POC)测试,它可以通过检测血液中的艾滋病毒遗传物质来诊断婴儿感染艾滋病毒。专门为发展中国家环境设计的Samba结果在两个小时内就准备好了。该测试有两个版本,定性测试(用于婴儿诊断)和半定量测试(用于治疗监测)。这项建议描述了一项Samba POC病毒学测试的整群随机试验,以改善赞比亚艾滋病毒感染儿童的结局。POC技术将被放置在初级保健地点,并提供两项功能:(1)为感染艾滋病毒的母亲所生的婴儿在出生6周时提供当天的早期艾滋病毒诊断,以及(2)对儿童进行抗逆转录病毒治疗的治疗监测。将有12个设施参加试验。一半的地点将被随机分配来实施POC技术,另一半将采用当前的护理标准-婴儿诊断在现场以外进行,治疗监测主要基于临床评估。这项试验的主要结果将是每个研究小组中感染艾滋病毒的儿童在首次诊断后18个月仍活着、在护理中、血液中没有艾滋病毒循环(治疗成功的一个指标)的比例。该研究将由赞比亚传染病研究中心(CIDRZ)进行。CIDRZ成立于2001年,由提出这项研究的团队领导,在NIH赞助的研究和PEPFAR赞助的服务实施方面都拥有丰富的经验。 公共卫生相关性:尽管预防艾滋病毒母婴传播的干预措施越来越多,但赞比亚等发展中国家的许多儿童无法逃脱感染。识别受感染的新生儿并立即开始抗逆转录病毒治疗具有深远的生存效果。这项建议概述了一项临床试验,以检验一种新的医疗点诊断技术在现场识别受感染儿童的有效性。 并立即开始进行救命的抗逆转录病毒治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY Samuel Allen STRINGER其他文献

JEFFREY Samuel Allen STRINGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY Samuel Allen STRINGER', 18)}}的其他基金

A Randomized Trial of 17-Hydroxyprogesterone Caproate (17P) to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy
17-羟基孕酮己酸酯 (17P) 减少妊娠期接受抗逆转录病毒治疗的妇女早产的随机试验
  • 批准号:
    9360140
  • 财政年份:
    2016
  • 资助金额:
    $ 96.5万
  • 项目类别:
A Randomized Trial of 17-Hydroxyprogesterone Caproate (17P) to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy
17-羟基孕酮己酸酯 (17P) 减少妊娠期接受抗逆转录病毒治疗的妇女早产的随机试验
  • 批准号:
    9769543
  • 财政年份:
    2016
  • 资助金额:
    $ 96.5万
  • 项目类别:
A Randomized Trial of 17-Hydroxyprogesterone Caproate (17P) to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy
17-羟基孕酮己酸酯 (17P) 减少妊娠期接受抗逆转录病毒治疗的妇女早产的随机试验
  • 批准号:
    9271471
  • 财政年份:
    2016
  • 资助金额:
    $ 96.5万
  • 项目类别:
Point-of-care virologic testing to improve outcomes of HIV-infected children
护理点病毒学检测可改善艾滋病毒感染儿童的预后
  • 批准号:
    8691716
  • 财政年份:
    2012
  • 资助金额:
    $ 96.5万
  • 项目类别:
Point-of-care virologic testing to improve outcomes of HIV-infected children
护理点病毒学检测可改善艾滋病毒感染儿童的预后
  • 批准号:
    8500183
  • 财政年份:
    2012
  • 资助金额:
    $ 96.5万
  • 项目类别:
International
国际的
  • 批准号:
    7685026
  • 财政年份:
    2009
  • 资助金额:
    $ 96.5万
  • 项目类别:
International Research
国际研究
  • 批准号:
    7697012
  • 财政年份:
    2008
  • 资助金额:
    $ 96.5万
  • 项目类别:
Centre for Infectious Diseases Research in Zambia HIV/AIDS Clinical Trials Unit
赞比亚传染病研究中心艾滋病毒/艾滋病临床试验单位
  • 批准号:
    7995968
  • 财政年份:
    2007
  • 资助金额:
    $ 96.5万
  • 项目类别:
Centre for Infectious Diseases Research in Zambia HIV/AIDS Clinical Trials Unit
赞比亚传染病研究中心艾滋病毒/艾滋病临床试验单位
  • 批准号:
    8451508
  • 财政年份:
    2007
  • 资助金额:
    $ 96.5万
  • 项目类别:
Centre for Infectious Diseases Research in Zambia HIV/AIDS Clinical Trials Unit
赞比亚传染病研究中心艾滋病毒/艾滋病临床试验单位
  • 批准号:
    8197844
  • 财政年份:
    2007
  • 资助金额:
    $ 96.5万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 96.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了